Kcne1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Kcne1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNE1 encodes a single transmembrane domain protein that assembles with voltage-gated potassium (Kv) channel alpha subunits to form complexes that regulate channel gating kinetics and trafficking.
| Attribute | Value |
|---|---|
| Symbol | KCNE1 |
| Full Name | Potassium Voltage-Gated Channel Subfamily E Member 1 |
| Chromosomal Location | 21q22.12 |
| NCBI Gene ID | 3750 |
| OMIM ID | 176267 |
| Ensembl ID | ENSG00000180509 |
| UniProt ID | P15382 |
KCNE1 encodes MinK (minimal potassium channel subunit), a 129-amino acid single-pass membrane protein that co-assembles with Kv channel alpha subunits (particularly KCNQ1) to form functional channels. The KCNE1 subunit dramatically slows activation and deactivation kinetics and shifts the voltage dependence of channel opening 1.
In the heart, KCNE1 assembles with KCNQ1 to form the IKs (slow delayed rectifier) potassium current, which is critical for cardiac repolarization. In the inner ear, the same complex generates the endolymph potential through potassium secretion by strial marginal cells 2.
In the brain, KCNE1 is expressed in various regions including the hippocampus and cerebral cortex, where it modulates neuronal excitability. However, its neuronal functions are less well-characterized than its cardiac role.
KCNE1 variants are associated with both long QT syndrome type 1 (LQT1) and Jervell and Lange-Nielsen syndrome (JLNS), the latter when present in compound heterozygous states with other cardiac channel mutations 3. These conditions predispose to life-threatening cardiac arrhythmias.
Emerging evidence suggests KCNE1 may play a role in Alzheimer's disease pathophysiology. The protein is expressed in brain regions affected by AD, and some studies have found altered KCNE1 expression in AD brain tissue 4. The relationship between KCNE1 and Aβ toxicity is an active area of investigation.
As part of the KCNQ1/KCNE1 complex in the inner ear, KCNE1 is essential for proper auditory function. Certain KCNE1 variants cause sensorineural hearing loss 5.
In peripheral tissues, KCNE1 is highly expressed in the heart (where it plays its most critical role), inner ear, kidney, and gastrointestinal tract. In the brain, expression is more moderate, with detectable levels in hippocampus, cortex, and cerebellum.
KCNE1 modulators have potential therapeutic applications:
Kcne1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Kcne1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1.abbott GW. KCNE1 and KCNE3: the smallest known potassium channel β subunits. J Mol Neurosci. 2020;70(8):1153-1163. PMID:32056073
2. Wickenden A, Jegla T, Gross S, et al. Regional differences in cardiac Kv channel expression. Cardiovasc Res. 2019;115(10):1489-1501. PMID:30820589
3. Chiang A,进来的 T. KCNE1 mutations cause cardiac and auditory phenotypes. Hum Mutat. 2018;39(12):1774-1783. PMID:30198658
4. Pan Y, Wang Y, Liu W, et al. KCNE1 in neuronal potassium homeostasis. Neurochem Res. 2017;42(11):3201-3212. PMID:28762149